Prescient Therapeutics Limited
PTX
Rank in Stocks
#23070
Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage... Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing several clinical trials: Phase 2a for HER2-negative breast cancer, Phase 1B/2 for acute myeloid leukemia that has relapsed or is resistant to treatment, and Phase 1b for ovarian cancer that is recurrent, persistent, or resistant to platinum-based therapies. Additionally, PTX-100, a RhoA inhibitor, is being developed to target both blood cancers and solid tumors, specifically those characterized by Ras and RhoA genetic mutations. Prescient Therapeutics has also forged a strategic alliance with The University of Texas MD Anderson Cancer Center to advance the development of a blood cancer binder for their OmniCAR platform. Founded in Melbourne, Australia, in 1986, the company operated as Virax Holdings Limited until its rebranding as Prescient Therapeutics Limited in December 2014.
Share Price
$0.04014702
Last synced: 2026-11-10
Market Cap
$45.92M
Change (1 day)
-1.69%
Change (1 year)
33.49%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Prescient Therapeutics Limited (PTX)
Category
Healthcare
Operating Margin for Prescient Therapeutics Limited (PTX)
Operating Margin as of November 2026 TTM: 0.00%
According to Prescient Therapeutics Limited's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -172.98%.
Operating Margin history for Prescient Therapeutics Limited from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -172.98% | -10.65% |
| 2024 | -193.59% | -52.45% |
| 2023 | -407.17% | 8.34% |
| 2022 | -375.81% | -17.94% |
| 2021 | -457.98% | 4.87% |
| 2020 | -436.73% | 29.80% |
| 2019 | -336.47% | -12.31% |
| 2018 | -383.71% | 24.81% |
| 2017 | -307.43% | 76.50% |
| 2016 | -174.18% | -78.97% |
| 2015 | -828.40% | -94.84% |
| 2014 | -16,052.57% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | -100.00% |
| 2008 | -450.29% | 45.60% |
| 2007 | -309.27% | -86.49% |
| 2006 | -2,289.47% | 661.38% |
| 2005 | -300.70% | 0.00% |
| 2004 | 0.00% | -100.00% |
| 2003 | -2,183.76% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
| 2000 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Prescient Therapeutics Limited's operating margin
What was Prescient Therapeutics Limited's operating margin in 2025?
In 2025, Prescient Therapeutics Limited's operating margin was -172.98%, compared with -193.59% in 2024.
How has Prescient Therapeutics Limited's operating margin changed since 2020?
From 2020 to 2025, Prescient Therapeutics Limited's operating margin was highest in 2025 (-172.98%) and lowest in 2021 (-457.98%).
How does Prescient Therapeutics Limited's operating margin compare with similar companies?
Prescient Therapeutics Limited's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.